Double attack on SARS

Double attack on SARS
© Thinkstock

After the SARS-CoV (severe acute respiratory syndrome coronavirus) outbreak in 2003, academia experts in immunology and molecular biology joined forces with industrial vaccine production experts in order to develop preventive and therapeutic measures for SARS.

Despite the fatality of the SARS-CoV outbreak in Asia, the rising and quarantine measures managed to contain viral spread. However, it is believed that the SARS-CoV has not been fully eradicated and as a result, a vaccine as well as an immediate and effective are much needed.

To this end, scientists on the EU-funded 'Immunoprevention and immunotherapy of SARS infection' (Sarsvac) project proposed to follow a vaccination approach coupled with an immunotherapeutic regimen.

More specifically, the strategy for vaccine development consisted of two parallel approaches: the preparation of a classical vaccine made with attenuated SARS-CoV and the identification of potentially immunogenic viral antigens. These antigens were planned to be expressed in a vector-based vaccine for generating specific immunity against the virus.

Additionally, partners studied SARS-CoV–derived virus-like particles (VLPs) in order to understand the morphogenesis and maturation of virions. The information they obtained allowed them to identify specific epitopes that offered protective T and B cell-mediated immunity.

As an immunotherapeutic strategy, neutralising to SARS-CoV were developed and validated. The plan was to administer these as a treatment option to patients already infected with the virus.

The Sarsvac approach promises an immediate and long-term protection against a potential SARS-CoV infection. Commercial exploitation of this vaccine and immunotherapy combination may prove the solution against a future SARS-CoV outbreak.

add to favorites email to friend print save as pdf

Related Stories

Study looks at Chinese herb use for SARS

Jan 25, 2006

Scientists at the West China Hospital in Sichuan say they've found the addition of Chinese herbs to current SARS therapy does not decrease death rates.

Protein from algae shows promise for stopping SARS

May 20, 2009

A protein from algae may have what it takes to stop Severe Acute Respiratory Syndrome (SARS) infections, according to new research. A recent study has found that mice treated with the protein, Griffithsin (GRFT), had a 100 ...

New test speeds up SARS detection

Aug 01, 2007

In the fight against epidemics, those battling on the front lines may be on the verge of a new weapon, thanks to a team of University of Alberta researchers.

Study: SARS can infiltrate brain tissue

Sep 15, 2005

Severe acute respiratory syndrome is a disease of the respiratory tract and now scientists say they've found SARS can also infiltrate brain tissue.

Recommended for you

Guidelines presented for diagnosing focal liver lesions

6 hours ago

(HealthDay)—Focal liver lesions (FLLs) are mostly benign, and can be diagnosed based on knowledge of their presentation, associated clinical and laboratory features, and natural history, according to clinical ...

Factors tied to neck, back pain improvement identified

10 hours ago

(HealthDay)—Observational registry-based research can inform patients and physicians about prognosis for subacute or chronic neck or low back pain, according to a study published in the Aug. 1 issue of ...

User comments